FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212 | -55.5% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $476 | -16.5% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $570 | -43.5% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $1,009 | -90.8% | 100 | -78.7% | 0.00% | -100.0% |
| Q3 2022 | $11,000 | -8.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $12,000 | -33.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $18,000 | -33.3% | 470 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $27,000 | -3.6% | 470 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $28,000 | -31.7% | 470 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $41,000 | +5.1% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $39,000 | -25.0% | 470 | -17.5% | 0.00% | -25.0% |
| Q4 2020 | $52,000 | +333.3% | 570 | +83.9% | 0.00% | +300.0% |
| Q3 2020 | $12,000 | +9.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $11,000 | +57.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $7,000 | – | 310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |